Abstract
OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (
| Original language | English |
|---|---|
| Pages (from-to) | 1025-1028 |
| Number of pages | 4 |
| Journal | Annals of Pharmacotherapy |
| Volume | 27 |
| Issue number | 9 |
| DOIs | |
| State | Published - 1993 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Randomized, controlled trial of transdermal clonidine for smoking cessation. / Hilleman, Daniel E.; Mohiuddin, Syed M.; Del Core, Michael; Lucas, B. Daniel.
In: Annals of Pharmacotherapy, Vol. 27, No. 9, 1993, p. 1025-1028.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Randomized, controlled trial of transdermal clonidine for smoking cessation
AU - Hilleman, Daniel E.
AU - Mohiuddin, Syed M.
AU - Del Core, Michael
AU - Lucas, B. Daniel
PY - 1993
Y1 - 1993
N2 - OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (
AB - OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (
UR - http://www.scopus.com/inward/record.url?scp=0027429314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027429314&partnerID=8YFLogxK
U2 - 10.1177/106002809302700901
DO - 10.1177/106002809302700901
M3 - Article
VL - 27
SP - 1025
EP - 1028
JO - Annals of Pharmacotherapy
JF - Annals of Pharmacotherapy
SN - 1060-0280
IS - 9
ER -